1 drugs added to China national insurance for diabetes
Pfizer and Innovent Biologics' GLP-1 drugs will be added to China's national insurance scheme for type 2 diabetes from January 1, per the National Healthcare Security Administration. This move may impact Novo Nordisk, whose Ozempic sales in China fell 7% in 2025. Eli Lilly and JW Therapeutics also have drugs added to the list.
How this was made
The 30-second read
Why it matters
The move broadens market access for Pfizer but introduces pricing pressure; competitors may see share erosion.
Market read
Regulatory inclusion in China could shift sales dynamics for GLP-1 manufacturers, affecting global diabetes drug market.
What to watch
Potential for combo therapies with existing Pfizer portfolio could enhance long‑term earnings.
Background
China's National Healthcare Security Administration is expanding its reimbursement list for GLP-1 drugs, adding Pfizer and Innovent products alongside existing Novo Nordisk and Eli Lilly offerings.
Ticker impact
Pfizer's GLP-1 drug ecnoglutide added to China's national insurance list, expanding market access.
likely modest pressure as market prices in lower reimbursement rates
Regulatory approval opens a large market but historically leads to price cuts, limiting upside.
Market effects
broader GLP-1 class faces increased competition in China, may compress margins for peers.
Chinese diabetes market expands, boosting overall pharma exposure to China.
signals regulatory openness that could influence other emerging markets' reimbursement policies.
Counterpoint
Price cuts may be offset by volume surge, offering upside if Pfizer can capture market share quickly.
Key entities
- companyPfizer
US pharmaceutical giant gaining Chinese insurance coverage for ecnoglutide.
- companyInnovent Biologics
Chinese biotech adding mazdutide to the same list.




